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27 Objectives: This study tests the hypothesis that individuals who achieve a plateau at 𝑉
28 O2max ( O2plat) are more likely to possess alleles, associated with anaerobic capacity, 𝑉
29 than those who do not. 
30 Design: A literature survey, physiological testing and genetic analysis was used to 
31 determine any association between the aerobic and anaerobic polymorphisms of 40 
32 genes and O2plat. 𝑉
33 Methods: 34, healthy, Caucasian volunteers, completed an exercise test to determine 
34 O2max, and O2plat. 28 of the volunteers agreed to DNA testing and 26 were 𝑉  𝑉
35 successfully genotyped. A literature search was used to determine whether the 40 
36 polymorphisms analysed were associated with aerobic, or anaerobic exercise 
37 performance.
38 Results: The literature survey enabled classification of the 40 target alleles as aerobic 
39 [11], anaerobic [24], or having no apparent association (NAA) [5] with exercise 
40 performance. It also found no previous studies linking a genetic component with the 
41 ability to achieve O2plat. Independent t-tests showed a significant difference (p < 𝑉
42 0.001) in the ability to achieve O2plat, but no other measured physiological variable 𝑉
43 was significantly different. Pearson’s χ2 testing demonstrated a highly significant 
44 association (p = 0.008) between anaerobic allele frequency and O2plat, but not with 𝑉 𝑉
45 O2max. There was no association between aerobic alleles and O2plat, or O2max. 𝑉 𝑉
46 Finally there were no significant differences in the allelic frequencies, observed in this 
47 study and those expected of Northern and Western European Caucasians. 
48 Conclusion: These results support the hypothesis that the ability to achieve O2plat is 𝑉
49 associated with alleles linked to anaerobic exercise capacity. 
50
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78 Factors contributing to athletic performance are complex, involving the 
79 interaction of numerous factors including training methods, psychology, technology, 
80 diet, and genetics.1 Of these, genetic factors are a major component, with overall 
81 heritability of athletic status estimated at ca. 66%. Despite this no single gene, or 
82 polymorphism, has been definitely associated with elite athletes, in any given sport.2 
83 Accordingly identifying genetic variants that contribute to athletic success has been 
84 challenging with at least 200 genetic polymorphisms, both nuclear and mitochondrial, 
85 been associated with athletic achievement.3 Recent studies have primarily focused on 
86 either endurance,3 or power (sprint) performance 4 and their associated 
87 polymorphisms. Typically such studies have concentrated on relatively few genes 
88 (e.g. ACE, ACTN3, AMPD1, NOS3, PGC1A, PPARG), however conflicting 
89 findings, even within the same populations, means their exact influence has not been 
90 fully resolved.1
91 An important contributor to athletic performance is maximal oxygen uptake (𝑉
92 O2max), which is a measure of aerobic power and cardio-respiratory fitness.3,5 
93 Classically O2max is based on the levelling off, or plateau, in oxygen uptake, despite 𝑉
94 a continued increase in exercise intensity.5 However many participants fail to reach 𝑉
95 O2plat, for a variety of reasons, including experimental methodology, modelling 
96 approaches and populations tested.5 Previous research has also attributed the ability to 
97 attain a O2plat to a greater reliance, in some individuals, on oxygen-independent 𝑉
98 (anaerobic) metabolism,6 also referred to as “anaerobic capacity”. Green7 defined 
99 anaerobic capacity as “the maximal amount of ATP resynthesised via anaerobic 
100 metabolism during a specific type of short duration maximal exercise”.  Examination 
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101 of power–duration relationships shows that exercise, above O2max, involves an 𝑉
102 increased recruitment of type II muscle fibres, to maintain power output.8 Accordingly 
103 it is reasonable to expect that individuals with greater anaerobic capacity and/or an 
104 increased proportion of type II muscle fibres will perform better in short duration 
105 sprint-type activities. Moreover they should also be able to increase their power 
106 output, when already working at O2max  and more readily achieve a O2plat.7,8 Clearly 𝑉 𝑉
107 the ability to increase work rate when already at O2max, using anaerobic metabolism, 𝑉
108 can be an important determinant of athletic performance. Thus  in 5km and 8km races, 
109 finish place and run-time is correlated with anaerobic, rather than aerobic capacity.9 
110 Hence it is surprising that there are no studies, to date, which have investigated a 
111 genetic component to the ability to achieve a O2plat.1,3 𝑉
112 Accordingly the aim of this study is to test the hypothesis that individuals who 
113 achieve O2plat are more likely to possess polymorphisms, associated with increased 𝑉
114 anaerobic capacity, than those who do not.
115
116 2. Methods
117 Following institutional ethical approval (Faculty of Science and Engineering Research 
118 Ethics Panel, Anglia Ruskin University, UK. FST/FREP/12/339), 34 recreationally 
119 competitive, Caucasians (29 males, 5 females; age = 27.5 ± 3.29 years, mass = 73.1 ± 
120 10.8 kg, stature = 179 ± 8 cm), recruited from a student population, volunteered for 
121 this study. All participants were provided with full, written, information about the 
122 experimental procedures and any associated risks before signing an informed consent 
123 form, as per the Helsinki declaration 1975 (revised 2013), to permit their 
124 participation. Participants also completed a pre-exercise medical questionnaire to 
125 eliminate any with history of cardiopulmonary diseases, diabetes, or recent (within 3 
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126 months) musculoskeletal injuries. Finally all participants were asked to read and sign 
127 a second informed consent form giving permission to sample and test their DNA for 
128 specific polymorphisms.
129 Before testing participants were instructed that they should not eat for 3 hours before 
130 testing and ensure that they arrived in a well-hydrated state, without having consumed 
131 alcohol, or caffeine, for 24 hours. They were also requested not to complete any 
132 heavy training sessions, within 48 hours, either side of testing. All participants 
133 attended a laboratory habituation visit to familiarise themselves with test equipment 
134 and procedures. During this visit each participant’s preferred seat and handlebar 
135 heights was recorded for their subsequent test visit.
136  Prior to all trials a metabolic cart (Metalyzer 3B, Cortex, Leipzig, Germany) 
137 was calibrated for both volume and flow using a 3 L syringe (Hans Rudolph, Kansas, 
138 USA), to establish linearity and reproducibility. Additionally a two-point gas 
139 calibration was undertaken using 15% CO2 and 0% O2 in balanced nitrogen (BOC, 
140 Nottingham, UK) and ambient O2.5,6  All exercise testing was performed using a pre-
141 calibrated cycle ergometer (Lode, Excalibur Sport, Groningen, Netherlands.  A low 
142 resistance turbine and facemask was used to determine respiratory volumes and flow 
143 rates. Using a sampling rate of 60 ml.min-1, expired O2, CO2 and N2 concentrations 
144 were measured, while being drawn, directly, from the turbine assembly, into the 
145 metabolic cart. Gas concentrations and respiratory kinetics were aligned using custom 
146 metabolic cart software, allowing calculation of gas exchange variables ( O2, CO2, 𝑉 𝑉
147 E and RER). Heart rate was continually monitored, throughout each exercise trial, 𝑉
148 using a short-range telemetric monitoring system (Polar 810s, Kemple, Finland).5 
149 Immediately after each O2max trial capillary blood samples (5 μl) were collected, for 𝑉
150 lactate analysis (GM7 Micro-Stat analyser, Analox Instruments, UK). As before, the 
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151 Micro-Stat analyser was calibrated, as per manufacturers’ instructions, before 
152 analysis, with all samples being measured immediately upon collection.10
153 To determine O2max and associated cardio-respiratory responses, participants 𝑉
154 completed an incremental exercise stress test, to volitional exhaustion, on a pre-
155 calibrated cycle ergometer, using a ramp rate of 0.42 W.s-1, with a starting resistance 
156 of 50 W (females), 100 W (males), at a minimum cadence of 60 rpm.  Tests were 
157 terminated, either through volitional withdrawal, or if cadence decreased by > 5 rpm 
158 of that prescribed, despite strong verbal encouragement. Throughout the course of the 
159 test, expired air and gas exchange variables were recorded on a breath-by-breath 
160 basis. Prior to the incremental test the participants undertook a self-selected warm-up 
161 with a duration of 5.2 ± 0.8 min. All testing protocols were in accordance with 
162 previous work.5,6,10 A confirmation of  O2max  was determined by the participant 𝑉
163 recording a ∆ O2 of ≤ 1.5 ml.kg-1.min-1 across the final 2, consecutive, 30-breath 𝑉
164 sampling periods.5,10 Additional (secondary) methods were employed to confirm a 
165 maximal effort, namely a respiratory exchange ratio (RER)  ≥ 1.15; maximal heart 
166 rate (HRmax) of  > 205.9 – 0.685.age  and peak blood lactate (pBLa) ≥ 8.0 mmol.5,10
167 For DNA testing participants were instructed not to eat/drink/smoke/clean 
168 teeth for 3 h prior to sampling. On arrival they were given a coded, sterile, plastic tube 
169 and a cotton wool swab-stick (FitnessGenes Ltd, DiagnOx Laboratory, 77 Heyford 
170 Park, Bicester, OX255HD, UK). This was used to collect a sample of buccal cells, by 
171 rubbing it against the inside of the cheek for 1 min, before sealing in the coded tubes, 
172 which were immediately sent to FitnessGenes Ltd., for genetic analysis. 
173 DNA was extracted using Qiagen DNA Blood Mini Kits. Samples were 
174 analysed, using allele-specific PCR11, for total of 40 putative exercise-associated 
175 genes.  Primers (Appendix A.1) were designed using Oligo Explorer 1.5 software and 
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176 checked for uniqueness using the NCBI BLASTW search engine 
177 (https://blast.ncbi.nlm.nih.gov/Blast.cgi). PCR was performed using a thermal cycler 
178 (Eppendorf Mastercycler Gradient; Eppendorf, Hamburg, Germany). The final 
179 volume of all PCR protocols was 25 μl. PCR conditions were as follows: initial 
180 denaturing at 95oC, 10 min.; 35 cycles at 95oC, 1 min.; 52 oC, 45 s; 72oC, 1 min.; with 
181 final extension at 72oC, 5 min. PCR products were subject to restriction enzyme 
182 digest and visualised by gel electrophoresis, using 1.2% agarose gels, for verification. 
183 Replicate samples were checked and if there was a mismatch, the genotyping was 
184 repeated. If, on repetition, no match was found, the sample was excluded from the 
185 final dataset. For the insertion/deletion (I/D) ACE polymorphism an indirect detection 
186 method was used, based on genotyping rs4341 (C/G; Appendix A.1), which is in total 
187 linkage disequilibrium with the I/D polymorphism.12 
188 A literature search was made of journals in PubMed, Google Scholar and Web 
189 of Science databases to determine which alleles of the 40 target alleles were 
190 associated with aerobic, or anaerobic performance, or whether they had NAA with 
191 exercise performance. Key words included the names of each gene and their SNPs 
192 (Appendix A.1), together with the terms: athlete, sport, exercise, physical 
193 performance, endurance, muscle, power, strength, sprint, aerobic, anaerobic, O2max,  𝑉
194 plateau and maximal oxygen consumption. Exclusion criteria were animal-based 
195 studies, articles not published in English and articles published before the year 2000.  
196 All statistical analyses were performed using the Statistical Package for Social 
197 Sciences (SPSS; Version 21.0, Chicago, Illinois, USA). Shapiro-Wilks and Levine 
198 tests showed all physiological and gas exchange data was normally distributed and 
199 with the exception of ∆ O2, to display homogeneity of variance. Two-tailed 𝑉
200 independent t-tests were used to test the null hypothesis that there were no differences 
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201 between physiological data from O2plat achievers and non-achievers. A further 𝑉
202 independent t-test was used to test the same null hypothesis for ∆ O2, but assuming 𝑉
203 unequal variance. Power calculations (α = 0.05, n = 34) suggested a statistical power 
204 > 95% for these analyses. Frequencies of alternative alleles, for each gene, were 
205 calculated using SPSS “Crosstabs” function.  Crosstabs also allowed Pearson’s χ2 
206 tests to determine whether the observed allelic frequencies of the participants differed 
207 from those of a wider, comparable, European population. Here expected allelic 
208 frequencies, calculated from data for Caucasians of Northern and Western European 
209 ancestry (HapMap-CEU genetic database: 
210 https://www.ncbi.nlm.nih.gov/SNP/index.html), were compared with the allelic 
211 frequencies found in this study. Allelic frequencies, for each gene, were also 
212 compared with O2plat and O2max, using Pearson’s χ2 tests on, either 3 × 2 𝑉 𝑉
213 contingency tables, where all 3 possible allelic combinations were present, or 2 x 2 
214 contingency tables for genes where only 2 of the possible 3 allelic combinations were 
215 observed. These analysis tested the null hypotheses that each gene’s allelic frequency 
216 had no association with either O2plat achievement, or with achievement of a “low”, or 𝑉
217 “high” O2max. The latter been defined as being lower, or higher, than the final 𝑉
218 group’s mean O2max (53.6 ml.kg-1.min-1). Results from these analyses enabled the 40 𝑉
219 polymorphisms  to be tabulated in order of the magnitude of their p - values, from 
220 lowest to highest, with respect to the allele’s association with O2plat achievement and 𝑉
221 O2max magnitude. Further 3 × 2 (2 x 2, excluding those genes with NAA) χ2 tests 𝑉
222 were performed to assess the distribution of aerobic and anaerobic alleles within the 
223 first 20 and second 20 positions, within these tables, with respect to p - values, for 
224 both O2plat and magnitude of O2max. Finally a regression analysis was performed to 𝑉 𝑉
225 determine any relationship between the values of O2max and Δ O2.𝑉 𝑉
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226 3. Results
227 A total of 2627 articles were identified. After deduplication, 2073 articles were 
228 scanned, based on title and abstract, following which a further 1986 articles were 
229 excluded. The remaining 87 articles enabled the 40 different polymorphisms to be 
230 classified either as primarily aerobic (11), anaerobic (24), or having NAA on exercise 
231 performance (5) (Table A.1). Alleles associated with muscle size/power and/or sprint 
232 performance were classified as “anaerobic”, whilst those associated with endurance 
233 performance, or increased O2max, were classified as “aerobic”. For some genes (e.g. 𝑉
234 ACE and ACTN3) their alternative alleles could be classified as either aerobic, or 
235 anaerobic.20 In this instance classification was made on the basis of the allele that 
236 appeared to have the greatest influence. Critically no references were found linking 
237 any genes, or their alleles, with O2plat achievement.𝑉
238
239 TABLE A.1 
240
241 Of the 34 participants 19 (56%) achieved O2plat, with both achievers and non-𝑉
242 achievers also meeting the various secondary criteria (RERmax, HRmax and pBLa), to 
243 confirm O2max. Only Δ O2 was significantly different (p < 0.001) for achievers (0.8 𝑉 𝑉
244 ± 0.39 ml.kg-1.min-1) and non-achievers (2.2 ± 0.68 ml.kg-1.min-1), respectively (Table 
245 A.2). Furthermore there were no significant differences for any other measured 
246 response variable: Time at O2max (s); CO2max (l.min-1); CO2max (ml.kg-1.min-1); 𝑉 𝑉 𝑉
247 Time at CO2max (s); RER at O2max; Time at RERmax (s); VEmax (l.min-1); End time 𝑉 𝑉
248 (s) (data not shown). Regression analysis (data not shown) found no relationship (r2 = 
249 0.044) between the magnitude of O2max and Δ O2.𝑉 𝑉
250
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251 TABLE A.2  
252
253 28 participants agreed to DNA testing and of these 26 participants were 
254 successfully genotyped (14 plateau achievers (54%) and 12 non-plateau achievers). 
255 This final group was identical to the original group in terms of their physiological 
256 responses (Table A.2). Crucially comparisons of their allelic frequencies, with 
257 frequencies obtained from the HapMap-CEU genetic database showed no significant 
258 differences (Table A.1).
259 Table A.3 shows that individuals who achieve O2plat are much more likely to 𝑉
260 possess polymorphisms associated with anaerobic performance than those who do 
261 not. Thus of the first 20 of the 40 genes tested (Table A.3) 16 had alleles classified as 
262 “anaerobic”, 2 “aerobic” and 2 “NAA”, whilst in the second 20, 8 alleles are 
263 classified as “anaerobic”, 9 “aerobic” and 3 “NAA” (χ2  = 7.32; p = 0.026). Excluding 
264 those genes classified as having NAA (χ2 = 7.10; p = 0.008) demonstrated that such a 




269 Manual inspection of the association of the alleles of genes (ACTN3, IL6, 
270 ADRB213, PPARG: Table A.3) with a significant, or very close to a significant 
271 association, with O2plat, (Table A.3) showed that for ACTN3 (C), IL6 (G) and 𝑉
272 PPARG (G), it was the anaerobic allele that predominated. Thus for ACTN3 the 
273 homozygous, CC, genotype was associated with 11 plateau achievers and only 3 non-
274 achievers. For IL6 the homozygous, GG, genotype was associated with 9 plateau 
275 achievers and only 3 non-achievers. In the case of PPARG, where only 2 of the 3 
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276 possible genotypes (CC and CG) were recorded, it was the CG genotype that was 
277 associated with plateau achievement. Finally the “aerobic” "ADRB213, (Table A.1), 
278 also showed a significant relationship with O2plat (Table A.3), where the AA (3) and 𝑉
279 GA (10) genotypes were associated with O2plat, compared with 5 non-achievers.𝑉
280 In contrast to the results for O2plat, there was no significant association of 𝑉
281 aerobic alleles with O2max (χ2 = 0.29; p = 0.86) (Table A.3).  Excluding those genes 𝑉
282 with NAA had no effect (χ2 = 0.06; p = 0.81). Only CYP1A2 showed a significant 
283 relationship with a higher than average O2max, with the aerobic PCG1A and ACE 𝑉
284 genes, being close to significance. For CYP1A2 the AA genotype was present in 13 




289 It is well-established that the ability to attain O2plat is inconsistent, with 𝑉
290 different studies reporting considerable variation in attainment. Possible explanations 
291 include methodology, such as O2 sampling intervals, protocol duration, modelling 𝑉
292 approaches and populations tested.5,6 There is also evidence that the ability to achieve 
293 O2plat has a physiological component, namely anaerobic capacity.6 Such a 𝑉
294 physiological component would, by necessity, be underpinned by a genetic 
295 component.4,17 The results of this study strongly support this hypothesis by 
296 demonstrating that possession of anaerobic alleles showed a highly significant 
297 association with O2plat attainment (Table A.3). Of those genes showing a significant 𝑉
298 relationship, ACTN3 4,13 showed the highest level of significance (p = 0.012). ACTN3 
299 codes for α-Actinin-3, a protein expressed in fast glycolytic type II fibres, which are 
300 responsible for rapid and powerful contractions during anaerobic activities, such as 
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301 sprinting and weightlifting.13 A common variant R577X (rs1815739 C/T) of this gene 
302 results in the replacement of an arginine codon (Arg or R) with a stop codon, (X), 
303 producing a non-functional α-actinin-3 protein. This slows the anaerobic metabolism 
304 of type II fibres, causing a shift toward increased oxidative metabolism.27 Since 
305 achieving  O2plat means increasing work rate, without further increase in oxygen 𝑉
306 consumption,5 it is not surprising that type II fibres, which can function under hypoxic 
307 conditions, such as are encountered at O2plat, could contribute to O2plat achievement. 𝑉 𝑉
308 IL6, which also showed a significant association with O2plat, is expressed in 𝑉
309 muscle cells, where it appears to have a role in hypertrophic muscle growth.17 As with 
310 this study, previous work reports that frequencies of the G allele were significantly 
311 higher in power athletes, compared with endurance athletes.17
312 The ability of muscles to operate under hypoxic conditions also provides an 
313 explanation for the significant association seen between ADRB213 and O2plat. 𝑉
314 Although ADRB213 was classified as “aerobic” (TableA.1),1,2 there is good evidence 
315 to suggest that it also confers an advantage when exercising under hypoxic 
316 conditions,28 such as those that will occur at O2plat. Here Tsianos et al.28, studying the 𝑉
317 Mount Olympus Marathon, which reaches an altitude of 2,690 m and represents a 
318 significant hypoxic challenge, found that A-allele of ADRB213 was associated with 
319 faster completion times.
320 In contrast to the strong association between anaerobic alleles and O2plat (Table A.3), 𝑉
321 there was no significant association with aerobic allelic frequency and O2max (Table 𝑉
322 A.3). Only one gene, CYP1A2, showed a significant association with O2max (Table 𝑉
323 A.3). CYP1A2 polymorphisms have been the subject of numerous studies because of 
324 their role in the metabolism of caffeine.29. Here the SNP in the CYP1A2 gene 
325 (163C>A; rs762551) is responsible for the haplotype which confers a faster capacity 
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326 to metabolize caffeine on AA homozygotes.30 Rapid production of these metabolites 
327 is believed to be responsible for performance-enhancing effects of caffeine among 
328 AA homozygotes.29 With respect to the significant association with CYP1A2 and 𝑉
329 O2max seen in this study, specifically the AA genotype, there is also increasing 
330 evidence that the AA genotype is overrepresented in endurance athletes,20 supporting 
331 the findings of this study.
332 Finally the allelic distribution of participants, in this study, did not differ 
333 significantly from those of Caucasians of Northern and Western European ancestry. 
334 This suggests the findings, described above, are likely applicable to this wider 
335 population group. Accordingly further research is required to confirm these findings 




340 This study has demonstrated that:
341  Allelic frequencies, of the participants, are representative of the wider 
342 Northern and Western European Caucasian population.
343  There is a statistically significant association of anaerobic alleles with O2plat 𝑉
344 attainment. 
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Table A.1 Genes, single nucleotide polymorphisms (SNP) and classification 
according to whether a specific nucleotide is associated with anaerobic, aerobic 
performance, or having no apparent association (NAA). A, T, G and C are the SNP-
specific nucleotide bases. Performance associated bases in bold. χ2 values (χ2 Freq) 
and p - values are for the allelic frequencies obtained in this study, compared with 
expected Northern and Western European Caucasian frequencies.
Gene SNP Anaerobic Aerobic Reference χ2 Freq p-value
ACE rs4341 G C 13 2.57 0.28
ACTN3 rs1815739 C T 13 3.62 0.16
ACVR1B* rs2854464 A G 14 0.02 0.99
ADRB213 rs1042713 G A 2 0.08 0.96
ADRB214 rs1042714 G C 2 0.09 0.96
AGT rs699 C T 14 5.69 0.06
AKT1 rs1130214 G T 4 0.09 0.96
AMPD1 rs17602729 C T 15 0.49 0.78
APOA2 rs5082 NAA NAA 16 1.68 0.43
APOA5* rs662799 NAA NAA 16 2.06 0.36
BDKRB2 rs1799722 C T 17 0.09 0.96
CKM rs8111989 G A 18 1.18 0.55
Clock rs1801260 NAA NAA 19 0.51 0.79
CNTF rs1800169 G A 14 0.49 0.78
CYP1A2 rs762551 C A 20 0.50 0.78
ESR1 rs722208 A G 21 0.25 0.88
FTO rs9939609 T A 22 2.32 0.31
HIF1A rs11549465 T C 17 1.2 0.55
IGF1-35* rs35767 T C 2 2.4 0.30
IGF1-71 rs7136446 C T 23 0.81 0.67
IGFBP-3 rs2854744 C A 23 2.62 0.27
IL15RA rs2296135 A C 17 2.41 0.31
IL6 rs1800795 G C 17 3.32 0.19
IL6R rs2228145 C A 17 0.92 0.63
MCM6* rs4988235 NAA NAA 24 3.18 0.34
MSTN* rs1805086 G A 25 1.34 0.51
MTHFR rs1801131 C A 17 0.24 0.88
MTR rs1805087 G A 2 1.94 0.38
MTRR rs1801394 G A 2 2.75 0.25
NOS3 rs2070744 T C 4 3.21 0.20
PGC1A rs8192678 G A 2 0.68 0.71
PPARA rs4253778 C G 2 0.08 0.95
PPARG* rs1801282 G C 2 1.23 0.54
SHBG rs1799941 A G 21 1.02 0.61
SLC16A1 rs1049434 T A 1 2.93 0.63
UCP1* rs6536991 NAA NAA 26 1.47 0.48
UCP2 rs660339 C T 1 0.16 0.92
UCP3 rs1800849 C T 1 0.08 0.96
VDR rs2228570 T C 14 3.54 0.17
VEGFA* rs2010963 G C 2 1.99 0.37
* Only 2 of the possible 3 allelic combinations present.
Table A.2. Physiological data for participants classified as plateau achievers, or non-
achievers, as described in methodology for all 34 participants (Original) and those 26 
participants (Final) who provided a DNA sample that was successfully analysed. 





















































Data are presented as means ± SD.
a Significant at the 99.9% level.
Table A.3. Results of χ2 analyses to determine; (A) the gene’s association with allelic 
frequency and presence/absence of O2plat (χ2 O2plat) and (B) to determine the gene’s 𝑉 𝑉
allelic frequency association (χ2 O2max) with low (< 53.6 ml.kg-1.min-1) and high 𝑉 𝑉
O2max (> 53.6 ml.kg-1.min-1). Genes are ordered with respect to increasing p -values for 
χ2 O2plat and χ2 O2max, respectively. Class = Classification: anaerobic (An), aerobic 𝑉 𝑉
(A), or no apparent association (NAA), as defined in Table1. 
A (gene) χ2 O2plat𝑉 p-value Class B (gene) χ2 O2max  𝑉 p-value Class
ACTN3 8.82 0.012a An CYP1A2 8.94 0.011a        A
IL6* 6.37 0.041a An PGC1A 4.53 0.10        A
ADRB213 6.04 0.049a A IL15RA 4.57 0.10      An
PPARG* 3.69 0.055 An ACE 3.72 0.15        A
IGFBP-3 4.1 0.13 An IGF1-71 3.49 0.17      An
VDR 3.74 0.15 An FTO 3.51 0.17      An
ESR1 3.75 0.15 An AKT1 3.48 0.17        A
CKM 3.75 0.15 An UCP1* 1.64 0.20  NAA
MTHFR 3.11 0.21 An BDKRB2 3.16 0.21        A
IGF1-71 2.85 0.24 An MTR 2.99 0.22      An
AGT 2.83 0.24 An ADRB214 2.94 0.23      An
HIF1A 2.82 0.24 An ADRB213 2.88 0.24        A
AMPD1 2.76 0.25 An MTHFR 2.83 0.24      An
FTO 2.69 0.26 An MSTN* 1.27 0.26      An
ACVR1B* 1.21 0.27 An AGT 2.67 0.26      An
MTR 2.51 0.28 An IGFBP-3 2.40 0.30      An
MCM6* 0.91 0.34 NAA NOS3 1.92 0.38      An
CNTF 2.16 0.32 An MTRR 1.86 0.39      An
UCP3 1.92 0.38 A APOA5* 0.65 0.42  NAA
APOA2 1.78 0.41 NAA VDR 1.66 0.44      An
CLOCK 1.67 0.43 NAA CNTF 1.63 0.44      An
NOS3 1.66 0.43 An PPARA 1.45 0.48       A
MTRR 1.65 0.44 An UCP3 1.44 0.49       A
UCP1* 0.52 0.47 NAA ESR1 1.37 0.50      An
APOA5* 0.48 0.49 NAA HIF1A 1.35 0.51      An
IL6R 1.41 0.49 An MCM6* 0.39 0.53  NAA
SLC16 1.41 0.49 A IGF1-35* 0.39 0.55     An
CYP1A2 1.36 0.51 A IL6R 1.17 0.56      An
VEGFA* 0.34 0.56 A CKM 1.13 0.57      An
ADBR214 1.36 0.51 An UCP2 1.13 0.57      A
PPARA 1.14 0.56 A CLOCK 1.05 0.59  NAA
BDKRB2 1.09 0.58 A IL6* 0.97 0.60      An
AKT1 0.75 0.68 A APOA2 0.96 0.62  NAA
PGC1A 0.56 0.75 A SLC16 0.92 0.62      A
IGF1-35* 0.07 0.79 An PPARG* 0.23 0.63     An
UCP2 0.36 0.83 A SHBG 0.65 0.72     An
ACE 0.36 0.83 A ACVR1B* 0.46 0.79     An
SHBG 0.36 0.84 An AMPD1 0.41 0.81     An
IL15RA 0.20 0.90 An ACTN3 0.08 0.96     An
MSTN* 0.01 0.92 An VEGFA* 0.06 0.97     A
* Only 2 of the possible 3 allelic combinations present.
Appendix A.1. Genes, SNPs and primers used, in this study, together with primer 
orientation.
Gene SNP Primer Orientation
ACE rs4341 GGGCTGGAGCTCAAG[C/G]CATTCAAACCCCTA Forward
ACTN3 rs1815739 CTGCCCGAGGCTGAC[C/T]GAGAGCGAGGTGCC Forward
ACVR1B rs2854464 GTGTTAGTGTCAGCC[A/G]TGGGAAATGAGCCA Forward
ADRB213 rs1042713 TTGCTGGCACCCAAT[A/G]GAAGCCATGCGCCG Forward
ADRB214 rs1042714 CACGACGTCACGCAG[C/G]AAAGGGACGAGGTG Forward
AGT rs699 CTGGCTGCTCCCTGA[T/C]GGGAGCCAGTGTGG Forward
AKT1 rs1130214 CCCAGGAGGTTTTTG[G/T]GCTTGCGCTGGAGG Forward
AMPD1 rs17602729 TAATGCAATACTCAC[A/G]TTTCTCTTCAGCTG Reverse
APOA2 rs5082 GGTCCTTGGACTTGA[A/G]TGCAACAGGAAGCA Reverse
APOA5 rs662799 AACTGGAGCGAAAGT[A/G]AGATTTGCCCCATG Forward
BDKRB2 rs1799722 AGGCTGATGACATCA[C/T]TACCCAGCCCTTGA Forward
CKM rs8111989 AGAAATGGGGAGCCA[G/A]GGCAGGTTCTTGAG Forward
Clock rs1801260 GTGATCATAGGGGCA[C/T]AGCCAGTTCTGACA Forward
CNTF rs1800169 TTTTCCTGTATCCTC[A/G]GCCAGGTGAAGCAT Forward
CYP1A2 rs762551 GTGAGCTCTGTGGGC[A/C]CAGGACGCATGGTA Forward
ESR1 rs722208 GGTGGGGTGGAAGAC[A/G]CTGAAATGAATTTT Forward
FTO rs9939609 GACTGCTGTGAATTT[A/T]GTGATGCACTTGGA Forward
HIF1A rs11549465 TTCGATCAGTTGTCA[C/T]CATTAGAAAGCAGT Forward
IGF1-35 rs35767 TTTTTTTTTTTTTCC[A/G]CATGACTCTCAGGG Reverse
IGF1-71 rs7136446 CACTGCCCTAAGTGC[C/T]GCGTAGTATGTGAA Forward
IGFBP-3 rs2854744 CGGGCTCCGGGCGTG[A/C]GCACGAGGAGCAGG Forward
IL15RA rs2296135 TTTCTCTGTGAACTG[A/C]AAGTTAGGATGAGG Forward
IL6 rs1800795 CTAGTTGTGTCTTNC[C/G]ATGCTAAAGGACGT Forward
IL6R rs2228145 TTAACCTAGTGCAAG[A/C]TTCTTCTTCAGTAC Forward
MCM6 rs4988235 GATAAGATAANGTAG[C/T]CCCTGGCCTCAAAG Forward
MSTN rs1805086 ACAATAAAGTAGTAA[A/G]GGCCCAACTATGGA Forward
MTHFR rs1801131 AGCTGACCAGTGAAG[A/C]AAGTGTCTTTGAAG Forward
MTR rs1805087 AAGATATTAGACAGG[A/G]CCATTATGAGTCTC Forward
MTRR rs1801394 CATNGCAGAAGAAAT[A/G]TGTGAGCAAGCTGT Forward
NOS3 rs2070744 AAGCTCTTCCCTGGC[T/C]GGCTGACCCTGCCT Forward
PGC1A rs8192678 GAAGCAGACAAGACC[A/G]GTGAACTGAGGGAC Forward
PPARA rs4253778 CTTGATATCTAGTTT[C/G]GATTCAAAAGCTTC Forward
PPARG rs1801282 GATTCTCCTATTGAC[C/G]CAGAAAGCGATTCC Forward
SHBG rs1799941 CTCCACCGCCCACAC[A/G]CAAGGCTGCCTGCC Forward
SLC16A1 rs1049434 CCAGAAAGACACAGA[A/T]GGAGGGCCCAAGGA Forward
UCP1 rs6536991 CCCAAAACATGTCTT[C/T]TCTTCACTGACATG Forward
UCP2 rs660339 CGGTACTGGGCGCTG[A/G]CTGTAGCGCGCACT Reverse
UCP3 rs1800849 TGGTCTTATACACAC[A/G]GGCTGACCTGAAAC Reverse
VDR rs2228570 CTGTTCTTACAGGGA[C/T]GGAGGCAATGGCGG Forward
VEGFA rs2010963 TGCGAGCAGCGAAAG[C/G]GACAGGGGCAAAGT Forward
